gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ABCLHealthcarePharmaceuticals

AbCellera Biologics Inc. Common Shares (ABCL)

$12.28+0.82%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$12.28▲ 152.16% in range
Nov 4, 2025Low $2.78 · High $14.82Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

AbCellera Biologics Inc. Common Shares closed at $12.28 on Nov 4, up 0.82%, 17.1% below its 52-week closing high. Volume of 2.7M shares was 0.67× its 20-day average (below normal).

Split-adjusted performance: -6.6% over one month, +143.7% over six months, +128.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $4.05M, down 76.3% from a year earlier, with a net margin of -1368.6%.

Short interest was 30.9M shares at the Oct 15 settlement, down 4.8% from the prior report (14.5% of float, 5.6 days to cover).

Market cap$3.98B324.0M shares
Revenue · quarter$4.0M−76.3% YoY
Diluted EPS$-0.18—
P/E · TTM—P/S 60.1×
Net margin-1,368.6%Gross 100.0%
Dividend yieldNone
52-week range2.78 – 14.82−17.1% from high
Volume2.7M0.67× 20-day avg
Volatility · 60d77.7%Annualised
Short % of float14.5%5.6 days to cover
Net cash$540.1MCash $540.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −10.0%1M −6.6%3M +88.1%6M +143.7%YTD +259.1%1Y +128.7%3Y +204.0%5Y −20.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum99
Revenue growth16
Net margin18
Value (low P/E)—
Size88

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short30.9M−4.8% vs prior
Days to cover5.6Settled Oct 15
% of float14.5%
Short vol. 10d44.2%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ABCLAbCellera Biologics$12.28+0.82%+143.7%−76.3%−1368.6%—$3.98B
TNGXTango Therapeutics$23.18+0.04%−1.9%−100.0%——$3.91BCompare
EWTXEdgewise Therapeutics$37.53−0.40%+1.5%———$4.08BCompare
XENEXenon Pharmaceuticals$39.19+2.51%−33.1%———$3.80BCompare
PBLSParabilis Medicines$30.36+3.79%——−45239.9%—$3.75BCompare
LQDALiquidia$47.38+12.27%+12.4%+1842.7%43.5%30.6$4.24BCompare
ARQTArcutis Biotherapeutics$34.05+6.41%+40.9%+59.3%11.6%150.1$4.28BCompare
ACADAcadia Pharmaceuticals$21.47+4.38%0.0%+16.4%10.2%9.7$3.70BCompare
IRONDisc Medicine$83.28+2.61%+21.3%———$3.70BCompare

News about AbCellera Biologics

All news →
Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCelleraGlobeNewswire Inc. · Oct 12, 2026▲ Positive

Quick answers

What does AbCellera Biologics Inc. Common Shares do?
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates.
What is ABCL's market cap?
$3.98B, based on the Nov 4 close of $12.28.
Does AbCellera Biologics Inc. Common Shares pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ABCL is sold short?
30.9M shares, 14.5% of float, as of Oct 15, 2026.
What sector is ABCL in?
Healthcare, in the Pharmaceuticals industry.

About AbCellera Biologics

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

HQ: Vancouver, A1562 employeesListed Dec 11, 2020abcellera.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology